厄贝沙坦与达格列净联用对糖尿病肾病患者糖脂指标、肾功能的影响

Irbesartan Paired in Therapy with Dapagliflozin on Glucose and Lipid Indexes and Renal Function in Patients with Diabetic Nephropathy

目的 研讨厄贝沙坦与达格列净联用对糖尿病肾病(diabetic nephropathy, DN)患者糖脂指标、肾功能的影响。方法 随机选取2021年2月—2024年2月福建省龙岩市第二医院收治的300例DN患者为研究对象,按照不同用药方案分为对照组和观察组,每组150例。对照组接受厄贝沙坦单药治疗,观察组基于对照组用药条件施加达格列净用药,对比两组方案药效、糖脂指标、肾功能以及用药安全性。结果 观察组治疗总有效率为92.67%(139/150),高于对照组的84.00%(126/150),差异有统计学意义(χ^(2)=5.466,P=0.019)。观察组经用药后空腹血糖、餐后2 h血糖、三酰甘油及总胆固醇水平均低于对照组,差异有统计学意义(P均<0.05)。观察组经用药后血肌酐值、24 h尿蛋白定量值与尿蛋白排泄率均低于对照组,差异有统计学意义(P均<0.05)。两组患者药物不良反应总发生率对比,差异无统计学意义(P>0.05)。结论 厄贝沙坦与达格列净联用治疗DN效果显著,对糖脂指标及肾功能有更理想的调节作用,并能够保障用药安全性。

Objective To investigate irbesartan paired in therapy with daglipin on glucose and lipid indexes and renal function in patients with diabetic nephropathy(DN).Methods A total of 300 cases DN patients admitted to the Second Hospital of Longyan City in from February 2021 to February 2024 were selected randomly as the research objects and divided into control group and observation group according to different medication regimens,with 150 cases in each group.The control group received irbesartan monotherapy,and the observation group was treated with dapagliflozin based on the medication conditions of the control group.The efficacy,glycolipid index,renal function and medication safety of the two groups were compared.Results The total effective rate of treatment in the observation group was 92.67%(139/150),which was higher than 84.00%(126/150)in the control group,and the difference was statistically significant(χ^(2)=5.466,P=0.019).The levels of fasting blood glucose,2 h postprandial blood glucose,triglyceride and total cholesterol in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).The serum creatinine value,24 h urinary protein quantitative value and urinary protein excretion rate in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of total adverse drug reactions between patients in two groups(P>0.05).Conclusion Irbesartan combined with dapagliflozin has significant effect in the treatment of DN,which can significantly improve the glucose and lipid indexes and renal function of patients,and ensure the safety of medication.